Adial’s AD04-103 study confirmed bioavailability, dose proportionality, and no food effect, supporting its 505(b)(2) FDA pathway. Study completion enables an End-of-Phase 2 FDA meeting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback